Interactions between Myc and Mediators of Inflammation in Chronic Liver Diseases

被引：60
作者：
Liu, Ting [1 ]
Zhou, Yu [2 ]
Ko, Kwang Suk [3 ]
Yang, Heping [4 ]
机构：
[1] Cent S Univ, Xiangya Hosp, Dept Gastroenterol, Changsha 410008, Hunan, Peoples R China
[2] Univ So Calif, Keck Sch Med, GI Liver Ctr, Los Angeles, CA 90033 USA
[3] Ewha Womans Univ, Coll Hlth Sci, Dept Nutr Sci & Food Management, Seoul 150750, South Korea
[4] Cedars Sinai Med Ctr, Dept Med, Div Gastroenterol, Los Angeles, CA 90048 USA
来源：
MEDIATORS OF INFLAMMATION | 2015年 / 2015卷
基金：
中国国家自然科学基金;
关键词：
NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; HEPATIC STELLATE CELLS; C-MYC; FATTY LIVER; SOLUBLE INTERLEUKIN-2-RECEPTOR; TRANSCRIPTION FACTORS; RECEPTOR ANTAGONIST; BILIARY-CIRRHOSIS; IL-8; EXPRESSION;
D O I：
10.1155/2015/276850
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
Most chronic liver diseases (CLDs) are characterized by inflammatory processes with aberrant expressions of various pro-and anti-inflammatory mediators in the liver. These mediators are the driving force of many inflammatory liver disorders, which often result in fibrosis, cirrhosis, and liver tumorigenesis. c-Myc is involved in many cellular events such as cell growth, proliferation, and differentiation. c-Myc upregulates IL-8, IL-10, TNF-alpha, and TGF-beta, while IL-1, IL-2, IL-4, TNF-alpha, and TGF-beta promote c-Myc expression. Their interactions play a central role in fibrosis, cirrhosis, and liver cancer. Molecular interference of their interactions offers possible therapeutic potential for CLDs. In this review, current knowledge of the molecular interactions between c-Myc and various well known inflammatory mediators is discussed.
引用
收藏
页数：12
相关论文
共 139 条
  • [21] Glycolytic rate and lymphomagenesis depend on PARP14, an ADP ribosyltransferase of the B aggressive lymphoma (BAL) family
    Cho, Sung Hoon
    Ahn, Annie K.
    Bhargava, Prerna
    Lee, Chih-Hao
    Eischen, Christine M.
    McGuinness, Owen
    Boothby, Mark
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2011, 108 (38) : 15972 - 15977
  • [22] Cytokines and alcohol
    Crews, FT
    Bechara, R
    Brown, LA
    Guidot, DM
    Mandrekar, P
    Oak, S
    Qin, LY
    Szabo, G
    Wheeler, M
    Zou, J
    [J]. ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2006, 30 (04) : 720 - 730
  • [23] de la Coste A, 1999, CANCER RES, V59, P5017
  • [24] Alterations of biliary biochemical constituents and cytokines in infantile hepatitis syndrome
    Ding, Yan
    Zhao, Lei
    Mei, Hong
    Huang, Zhi-Hua
    Zhang, Shu-Ling
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2006, 12 (43) : 7038 - 7041
  • [25] Hepatic Expression of CXC Chemokines Predicts Portal Hypertension and Survival in Patients With Alcoholic Hepatitis
    Dominguez, Marlene
    Miquel, Rosa
    Colmenero, Jordi
    Moreno, Montserrat
    Garcia-Pagan, Joan-Carles
    Bosch, Jaime
    Arroyo, Vicente
    Gines, Pere
    Caballeria, Juan
    Bataller, Ramon
    [J]. GASTROENTEROLOGY, 2009, 136 (05) : 1639 - 1650
  • [26] TGF-β in progression of liver disease
    Dooley, Steven
    ten Dijke, Peter
    [J]. CELL AND TISSUE RESEARCH, 2012, 347 (01) : 245 - 256
  • [27] Increased expression of c-Jun in nonalcoholic fatty liver disease
    Dorn, Christoph
    Engelmann, Julia C.
    Saugspier, Michael
    Koch, Andreas
    Hartmann, Arndt
    Mueller, Martina
    Spang, Rainer
    Bosserhoff, Anja
    Hellerbrand, Claus
    [J]. LABORATORY INVESTIGATION, 2014, 94 (04) : 394 - 408
  • [28] The development and compensation of biliary cirrhosis in interleukin-6-deficient mice
    Ezure, T
    Sakamoto, T
    Tsuji, H
    Lunz, JG
    Murase, N
    Fung, JJ
    Demetris, AJ
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 2000, 156 (05) : 1627 - 1639
  • [29] Fava Giammarco, 2010, World J Gastrointest Pathophysiol, V1, P12, DOI 10.4291/wjgp.v1.i1.12
  • [30] FERNANDEZ A, 1994, ONCOGENE, V9, P2009
12345678910